Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 7/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1864641 | 0.90 | SMN1; SMN2 (0.46) | CYP1A2CYP2C9CYP2C19TGM2MAPK3 | |
| SCHEMBL409556 | 0.83 | LMNA (0.54) | CYP2C19MAPK3SMN1; SMN2MAPTMEN1 | |
| SCHEMBL16123260 | 0.79 | CREBBP (0.51) | CYP1A2CYP2C9CYP2C19TGM2MAPK3 | |
| SCHEMBL10027972 | 0.79 | KDM4E (0.55) | CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL1862565 | 0.74 | FGFR4 (0.41) | CYP2C9CYP2C19TGM2FGFR1FGFR4 | |
| SCHEMBL18256266 | 0.74 | TGM2 (0.59) | CYP1A2CYP2C9CYP2C19TGM2MAPK3 | |
| SCHEMBL26840813 | 0.74 | ALDH1A1 (0.55) | SMN1; SMN2MAPTLMNARAB9AALDH1A1 | |
| SCHEMBL31162339 | 0.73 | MEN1 (0.61) | TGM2SMN1; SMN2MAPTMEN1LMNA | |
| SCHEMBL5078477 | 0.73 | MEN1 (0.61) | TGM2SMN1; SMN2MAPTMEN1LMNA | |
| SCHEMBL4211599 | 0.71 | TSHR (0.47) | SMN1; SMN2MAPTMEN1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939241-B2 | (Meth)acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method | NEC CORPORATION (JP) | 2011-05-10 | — | — | US | disclosed |
| US-7939241-B2 | (Meth)acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method | NEC CORPORATION (JP) | 2011-05-10 | — | — | US | disclosed |
| US-20090068587-A1 | (Meth) acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method | NEC CORPORATION (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20090068587-A1 | (Meth) acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method | NEC CORPORATION (JP) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068587-A1 | (Meth) acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method | MMAB, DNMT3A, MAT1A | CYP1A2 1026/4885CYP2C9 1166/4885CYP2C19 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.